FINEARTS-HF
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 6,001 patients with heart failure and an ejection fraction ≥ 40 %, finerenone reduced worsening-heart-failure events and cardiovascular death compared with placebo.
N
6.001
Design
Double-blind RCT
Endpunkt
Total worsening-HF events + CV death
Relevanz
2
ErgebnisRate ratio 0.84; CV death alone not significant; hyperkalaemia ~ 10 %.
Solomon SD, et al. N Engl J Med. 2024;391(16):1475-1485. 10.1056/NEJMoa2407107
Diskussion & Kritik
First non-steroidal MRA win in HFpEF/HFmrEF. Modest, hospitalisation-driven benefit; adds to SGLT2 inhibitors rather than replacing them.